Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 5.67%
As of Wednesday, July 29, Tectonic Therapeutic, Inc.’s TECX share price has dipped by 5.67%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Up 6.33%
As of Friday, July 17, Tectonic Therapeutic, Inc.’s TECX share price has surged by 6.33%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 5.06%
As of Wednesday, July 15, Tectonic Therapeutic, Inc.’s TECX share price has dipped by 5.06%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Up 7.91%
As of Thursday, July 02, Tectonic Therapeutic, Inc.’s TECX share price has surged by 7.91%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Up 5.05%
As of Tuesday, June 30, Tectonic Therapeutic, Inc.’s TECX share price has surged by 5.05%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | TECX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $537.4 | $251.9 | 38% |
|
| Shares Out (Mil) | 18.8 | 50.8 | 30% |
|
| Institutional Ownership | 67.4% | 92.0% | 42% |
|
| Float (Mil) | 11.2 | 40.5 | 21% |
|
| Beta | 0.10 | 0.95 | 8% |
|
| Avg Daily Volume (000s) | 157 | 447 | 41% |
|
| Price Change (52-week) |
27.7% | 54.2% | 68% |
|
| Growth | TECX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | na | (9.8%) | na |
|
| EPS (5yr) | na | 16.3% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TECX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($84) | ($43) | 12% |
|
| EPS (TTM) | ($4.458) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($65) | ($30) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($70) | $3 | 17% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $5 | 22% |
|
| Enterprise Value (Q1) (Mil) | $416 | $182 | 33% |
|
| Valuation | TECX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.33 | 2.60 | 56% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | TECX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (29.7%) | (49.7%) | 17% |
|
| ROE | (31.4%) | (55.4%) | 20% |
|
| Liabilities to Assets | 6.6% | 30.3% | 3% |
|
| F-Score | 2 | 3 | 7% |
|
Tectonic Therapeutic, Inc. did not pass any screens on 7/30/2026.
